Product Images Atorvastatin Calcium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Atorvastatin Calcium NDC 71610-116 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 20 mg - 71610 0116 45

Bottle Label 20 mg - 71610 0116 45

This is a description of a medication called Atorvastatin Calcium, which comes in the form of 20mg tablets. The pack contains 45 tablets. The rest of the text contains unreadable characters, but may be related to the product packaging or instructions.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Chemical Structure - atorvastatin calcium tablets 1

Chemical Structure - atorvastatin calcium tablets 1

Figure 1 - atorvastatin calcium tablets 2

Figure 1 - atorvastatin calcium tablets 2

The provided text seems to be a statistical data set containing numbers representing cumulative incidence percentages at different time intervals collected over a period of 35 years. It also includes the hazard ratio (HR) and p-value obtained from statistical analysis. However, there is not enough information or context to provide a clear description or interpretation of the data.*

Figure 2 - atorvastatin calcium tablets 3

Figure 2 - atorvastatin calcium tablets 3

The text describes survival analysis data where cumulative hazard percentage, HR (Hazard Ratio), and p-value are shown for 5 different time points up to 4 years of follow-up. The data suggests that there is a statistically significant difference in survival rates between the groups being compared.*

Figure 3 - atorvastatin calcium tablets 4

Figure 3 - atorvastatin calcium tablets 4

This is a statistical report on the effectiveness of Atorvastatin in reducing the occurrence of major cardiovascular events. The table shows the percentages of subjects experiencing the event (not available due to the error) with Atorvastatin 10 mg and 80 mg. The hazard ratio (HR) statistic indicates that Atorvastatin 80 mg had a greater reduction in the occurrence of the event compared to the 10 mg dose. The report also includes a graph illustrating the time to the first major cardiovascular endpoint over 4 years.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.